Tier 2 — strong

Oral administration of hyaluronic acid to improve skin conditions via a randomized double-blind clinical test

Yan-Rui Gao, Rui-Ping Wang, Lu Zhang, Yuan Fan, Jin Luan, Zhe Liu, Chao Yuan
Skin Research and Technology 2023 29(11):e13531

Bibliography

PubMed
PMID 38009035
PubMed Central
PMC10661223
DOI
10.1111/srt.13531
Competing interests
Three authors were affiliated with Bloomage Biotech Co., Ltd.

Study snapshot

DesignRandomized, double-blind, placebo-controlled dose-ranging clinical trial
Model129 healthy women aged 18–65 with dry, normal or oily skin
Samplen=129 enrolled
Intervention300 kDa oral HA at 100 mg/day or 200 mg/day versus placebo
Duration12 weeks
EndpointsSkin hydration; Skin tone; Epidermal thickness; Dermal density; Age-group and skin-type subgroup responses

What the study showed, in plain terms

This double-blind trial tested 100 mg/day and 200 mg/day of 300 kDa oral hyaluronic acid against placebo in 129 women with different ages and skin types.

Hydration improved during weeks 2–8 across several subgroups, with skin-tone changes reported at weeks 4–8 and increased epidermal thickness at 12 weeks.

The dose-ranging design is useful for the 100–200 mg range, although several reported analyses compare follow-up with baseline rather than consistently reporting direct placebo-group contrasts.

Key findings

  • 100 mg/day and 200 mg/day were tested using 300 kDa HA.
  • Skin hydration improved in multiple age and skin-type subgroups during follow-up.
  • Skin tone and epidermal thickness also showed favorable changes at selected time points.

What this study can and cannot tell us

  • All participants were female and recruited in one Chinese center.
  • Some analyses emphasize within-group change rather than clear between-group placebo comparisons.
  • Three authors were affiliated with an HA manufacturer.

Citation network

Articles citing this research paper

6 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology